Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before tomorrow’s bell. Given recent price action, a buy-the-dip scenario could be on the cards.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and pricing challenges loom. See more here.

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global pharmaceutical firm renowned for its innovative contributions to healthcare. The company has developed notable medications such as Prozac for depression,